An External Control Arm Study in Non-Small Cell Lung Cancer
A study to create control arms using current and future information in patients with lung cancer.
Checked against the public recordLast updated Aug 10, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- N-Power Medicine
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. \> 18 years of age at the time of informed consent 2. Pathologically confirmed locally advanced or metastatic NSCLC 3. ECOG Performance of less than or equal to 1 within 4 weeks prior to starting index therapy. 4. Life expectancy of more than 3 months 5. Able to understand and sign informed consent 6. Evidence of measurable disease (as assessed by the Investigator) on available imaging (e.g CT, MRI, PET) \*see protocol for cohort specific inclusion criteria\* Exclusion Criteria: 1. Actively on a clinical trial of an investigational agent 2. Currently receiving active systemic therapy for another malignancy 3. Eligible for treatment with curative intent \*see protocol for cohort specific exclusion criteria\*
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Pacific Cancer CareMonterey, California
- Bayhealth Medical Center, Kent CampusDover, Delaware
- Bayhealth Medical Center- Sussex CampusMilford, Delaware
- Northwest Oncology and HematologyBarrington, Illinois
- Northwest Oncology and HematologyElk Grove, Illinois
- Northwest Oncology and HematologyHoffman Estates, Illinois
- Northwest Oncology and HematologyRolling Meadows, Illinois
- Oncology ConsultantsHouston, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 10, 2026. Always confirm current availability with the study team.